Teva Pharmaceutical Industries Limited (NYSE:TEVA) Position Increased by Maverick Capital Ltd.

Maverick Capital Ltd. boosted its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 13.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 65,483 shares of the company’s stock after purchasing an additional 7,938 shares during the period. Maverick Capital Ltd.’s holdings in Teva Pharmaceutical Industries were worth $1,064,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. New Covenant Trust Company N.A. acquired a new position in Teva Pharmaceutical Industries in the first quarter worth approximately $28,000. EntryPoint Capital LLC bought a new position in shares of Teva Pharmaceutical Industries during the 1st quarter valued at $30,000. Beach Investment Counsel Inc. PA acquired a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at $48,000. Byrne Asset Management LLC bought a new stake in Teva Pharmaceutical Industries in the second quarter worth $52,000. Finally, Industrial Alliance Investment Management Inc. acquired a new position in Teva Pharmaceutical Industries during the first quarter worth $54,000. 54.05% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

TEVA has been the subject of a number of analyst reports. UBS Group boosted their price target on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Barclays upped their target price on Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the stock an “overweight” rating in a research report on Thursday, August 1st. StockNews.com lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Monday, September 23rd. Jefferies Financial Group raised their target price on shares of Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the company a “buy” rating in a research note on Thursday, June 27th. Finally, Argus upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a report on Wednesday, July 10th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and a consensus price target of $18.89.

Teva Pharmaceutical Industries Stock Down 1.6 %

NYSE TEVA opened at $17.46 on Friday. Teva Pharmaceutical Industries Limited has a twelve month low of $8.06 and a twelve month high of $19.08. The company has a debt-to-equity ratio of 2.52, a quick ratio of 0.59 and a current ratio of 0.89. The stock has a market cap of $19.78 billion, a PE ratio of -42.59, a PEG ratio of 1.23 and a beta of 0.88. The firm has a 50-day simple moving average of $17.75 and a 200 day simple moving average of $16.18.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $0.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.55 by $0.03. The company had revenue of $4.16 billion during the quarter, compared to analysts’ expectations of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. On average, research analysts forecast that Teva Pharmaceutical Industries Limited will post 2.33 EPS for the current year.

Insiders Place Their Bets

In other news, insider Eric A. Hughes sold 24,537 shares of the stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $17.25, for a total value of $423,263.25. Following the completion of the transaction, the insider now directly owns 45,060 shares of the company’s stock, valued at approximately $777,285. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 0.55% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.